Análisis del manejo de la nasofaringitis aguda en Atención Primaria en zona de salud rural. Un estudio descriptivo.

INTRODUCCIÓ: nasofaringitis aguda (NFA) malaltia infecciosa amb elevada morbiditat-demanda en Atenció Primària. OBJECTIUS: adherència dels metges a la guia semfyc, conèixer patró epidemiològic i despesa en NFA. MATERIAL: Disseny descriptiu, anys 2009-2010. Càlcul mostral Epidat, 269 pacients. Mostreig aleatori simple. Tractament estadístic SPSS. RESULTATS: No prescripció d'antibiòtics 86,1% (p &0,05). Prevalença NFA 14%. 1 consulta mèdica (85,4%). Complicacions (2,2%). Paracetamol-AINEs (62,9%), genèrics (65%). Diferències entre prescripció antibiòtica i edat (p = 0,025) menor no prescripció a & 80años (p = 0,025). Cost mitjà total 69.6 euros (54,7-188,8; DT 22,8). CONCLUSIONS: bona adherència, alta prevalença, poques complicacions, elevada prescripció de fàrmacs simptomàtics. Cost considerable.

Suboptimal Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients With Myocardial Infarction

Background: The incidence of cardiovascular events in HIV patients has fallen. Methods: We identified 81 patients with a history of coronary events from 2 hospitals in Spain to evaluate management of CVRF before and after the event. Results: The prevalence of coronary events was 2.15%. At the time of the coronary event, CVRF were highly prevalent. Decrease in total cholesterol (P=0.025) and LDLc(P=0.004) was observed. LDLc and HDLc were determined and the percentage of patients with LDLc &100 mg/dL remained stable at the last visit. Conclusions: The prevalence of coronary disease in our cohort was low. Although CVRF were highly.

Pretreatment with statins improves early outcome in patients with first-ever ischaemic stroke: a pleiotropic effect of statins or a beneficial effect of hypercholesterolemia?

Background: Data from different studies suggest a favourable association between pretreatment with statins or hypercholesterolemia and outcome after ischaemic stroke. We examined whether there were differences in in-hospital mortality according to the presence or absence of statin therapy in a large population of first-ever ischaemic stroke patients and assessed the influence of statins upon early death and spontaneous neurological recovery. Methods: In 2,082 consecutive patients with first-ever ischaemic stroke collected from a prospective hospital-based stroke registry during a period of 19 years (1986-2004), statin use or hypercholesterolemia before stroke was documented in 381 patients. On the other hand, favourable outcome defined as grades 0-2 in the modified Rankin scale was recorded in 382 patients. Results: Early outcome was better in the presence of statin therapy or hypercholesterolemia (cholesterol levels were not measured) with significant differences between the groups with and without pretreatment with statins in in-hospital mortality (6% vs 13.3%, P = 0.001) and symptom-free (22% vs 17.5%, P = 0.025) and severe functional limitation (6.6% vs 11.5%, P = 0.002) at hospital discharge, as well as lower rates of infectious respiratory complications during hospitalization. In the logistic regression model, statin therapy was the only variable inversely associated with in-hospital death (odds ratio 0.57) and directly associated with favourable outcome (odds ratio 1.32).

Alimentación, mortalidad y desarrollo de Cydia pomonella (L.) y de Cacoecimorpha pronubana (Hübner) sobre dieta con extracto de neem incorporado

Se han estudiado los efectos de 4 extractos del neem (Sukrina New ®, Rakshak ®, Margosan-O® y Azatin®) incorporados en la dieta larvaria sobre la alimentación, la mortalidad y el desarrollo de larvas de Cydia pomonella (L.) y de un extracto (Sukrina New ®) sobre Cacoecimorpha pronubana (Hübner) (ambos Lepidoptera, Tortricidae). C. pomonella fue más sensible a la acción de Sukrina New® que C. pronubana. Sobre esta última especie, no se detectaron cambios en el comportamiento de alimentación ni efectos sobre la mortalidad o la duración del desarrollo. Todos los extractos ensayados alteraron el comportamiento de alimentación de C. pomonella, cuyas larvas no penetraron en la dieta , pero sólo Azatin® mostró un efecto repelente o antiapetitivo. Margosan-O® y Rakshak® fueron los extractos más activos sobre C. pomonella, provocando un 100% de mortalidad a las concentraciones de 0,0625% y 0,025%, respectivamente. La mayoría de las larvas muertas presentaron síntomas asociados al proceso de la muda. Los individuos de C. pomonella alimentados con extracto de neem tuvieron un menor tamaño y una duración del desarrollo mayor que los de los testigos.

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

Background: The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist, were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Methods: In two double-blind, 52-week studies, ACCLAIM/COPD I (n = 843) and II (n = 804), patients were randomised to inhaled aclidinium 200 μg or placebo once-daily. Patients were required to have a postbronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity ratio of ≤70% and FEV1 <80% of the predicted value. The primary endpoint was trough FEV1 at 12 and 28 weeks. Secondary endpoints were health status measured by St George"s Respiratory Questionnaire (SGRQ) and time to first moderate or severe COPD exacerbation. Results: At 12 and 28 weeks, aclidinium improved trough FEV1 versus placebo in ACCLAIM/COPD I (by 61 and 67 mL; both p < 0.001) and ACCLAIM/COPD II (by 63 and 59 mL; both p < 0.001). More patients had a SGRQ improvement ≥4 units at 52 weeks with aclidinium versus placebo in ACCLAIM/COPD I (48.1% versus 39.5%; p = 0.025) and ACCLAIM/COPD II (39.0% versus 32.8%; p = 0.074). The time to first exacerbation was significantly delayed by aclidinium in ACCLAIM/COPD II (hazard ratio [HR] 0.7; 95% confidence interval [CI] 0.55 to 0.92; p = 0.01), but not ACCLAIM/COPD I (HR 1.0; 95% CI 0.72 to 1.33; p = 0.9). Adverse events were minor in both studies. Conclusion: Aclidinium is effective and well tolerated in patients with moderate to severe COPD. Trial registration: ClinicalTrials.gov: NCT00363896 ACCLAIM/COPD I) and NCT00358436 (ACCLAIM/COPD II).

Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients

There are conflicting data on the prevalence of coronary events and the quality of the management of modifiable cardiovascular risk factors (CVRF) inHIV-infected patients. Methods.We performed a retrospective descriptive study to determine the prevalence of coronary events and to evaluate the management of CVRF in a Mediterranean cohort of 3760 HIV-1-infected patients from April 1983 through June 2011. Results.We identified 81 patients with a history of a coronary event (prevalence 2.15%); 83% of them suffered an acute myocardial infarction. At the time of the coronary event, CVRF were highly prevalent (60.5% hypertension, 48% dyslipidemia, and 16% diabetes mellitus).OtherCVRF, such as smoking, hypertension, lack of exercise, and body mass index, were not routinely assessed. After the coronary event, a significant decrease in total cholesterol ( � = 0.025) and LDLcholesterol ( � = 0.004) was observed. However, the percentage of patients whomaintained LDL-cholesterol > 100mg/dL remained stable (from 46% to 41%, � = 0.103). Patients using protease inhibitors associated with a favorable lipid profile increased over time ( � = 0.028). Conclusions.The prevalence of coronary events in our cohort is low. CVRF prevalence is high and theirmanagement is far from optimal. More aggressive interventions should be implemented to diminish cardiovascular risk in HIV-infected patients.